Numbers of patients treated with disease modifying antirheumatic drugs during three periods: the previous four weeks, between the past four weeks and the past 12 months, and before the past 12 months
| DMARD | During the previous 4 weeks | Between the past 4 weeks and the past 12 months | Before the past 12 months | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| DMARD, disease modifying antirheumatic drug; TNF, tumour necrosis factor. | ||||||
| Methotrexate | 500 | 45.1 | 638 | 57.5 | 833 | 75.1 |
| Gold salts (intramuscular) | 54 | 4.9 | 90 | 8.1 | 587 | 52.9 |
| Hydroxychloroquine | 150 | 13.5 | 217 | 19.6 | 596 | 53.7 |
| Sulphasalazine | 118 | 10.6 | 191 | 17.2 | 479 | 43.2 |
| Anti-TNF | 156 | 17.1 | 179 | 17.9 | 185 | 17.2 |
| Leflunomide | 73 | 8.0 | 78 | 7.8 | 79 | 7.4 |
| Tiopronine | 30 | 2.7 | 50 | 4.5 | 262 | 23.6 |
| D-penicillamine | 14 | 1.3 | 25 | 2.3 | 251 | 22.6 |
| Cyclosporin | 35 | 3.2 | 59 | 5.3 | 120 | 10.8 |
| Azathioprine | 11 | 1.0 | 21 | 1.9 | 62 | 5.6 |
| Cyclophosphamide | 5 | 0.5 | 14 | 1.3 | 31 | 2.8 |
| Gold salts (oral) | 8 | 0.7 | 15 | 1.4 | 67 | 6.0 |
| Total number of patients treated | 911 | 82.1 | 999 | 90.1 | 1074 | 96.8 |
| Corticosteroids | 799 | 72 | ||||
| NSAID | 502 | 45.3 | ||||
| Non-opiate analgesics | 607 | 54.7 | ||||
| Opiate analgesics | 89 | 8 | ||||
| Gastroduodenal protective agents | 471 | 42.5 | ||||
| Antidepressive agents | 406 | 8 | ||||
| Anti-osteoporosis drugs | 89 | 36.6 | ||||
| Clinical trials | ||||||
| Yes | 191 | 17.8 | ||||
| No | 880 | 82.2 | ||||